News

Trump demands drug companies slash U.S. prices in blow to industry
Trump gave the companies 60 days to voluntarily comply, threatening to "deploy every tool in our arsenal to protect American families" if they don't.
Trump sends letters to pharma CEOs demanding they reduce drug prices in 60 days
President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical company CEOs on Truth Social.
Trump Pressures 17 Pharma CEOs to Cut US Drug Prices
Trump has given the companies until September 29 to respond with binding commitments to those terms. "According to recent data, the prices that Americans have been paying for brand name drugs are more than three times the price other similarly developed nations pay,
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping executive order aimed at lowering prices.
Trump is demanding drugmakers lower prices within 60 days. Pharma experts say it’s unlikely to happen.
President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ones available to patients in other countries — though industry experts don’t expect the pharmaceutical companies to acquiesce.
Trump Demands That Drugmakers Lower Some of Their U.S. Prices by September
President Trump on Thursday sent letters to 17 of the world’s biggest drugmakers demanding that they reduce some of their U.S. prices to the much lower levels they charge other wealthy countries by late September.
Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says
Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe ...
Josh Brown on Pfizer (PFE): ‘I Was Dead Wrong, There’s No Turnaround’
Pfizer Inc (NYSE:PFE) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Josh Brown, CEO of Ritholtz Wealth ...
Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability
The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid ...
Where Will Pfizer (PFE) Be in 5 Years?
Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief ...
Bondi made changes to DOJ policy. Her former client Pfizer might have benefited
The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the ...
Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Pfizer: Lack Of Enthusiasm Shouldn't Surprise You
Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.